Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 26, 2022 |
Sep. 30, 2022 |
Aug. 22, 2022 |
Jun. 26, 2022 |
Mar. 29, 2022 |
Dec. 31, 2021 |
Oct. 31, 2021 |
Sep. 30, 2022 |
Sep. 30, 2022 |
Dec. 31, 2020 |
Aug. 24, 2022 |
Nov. 30, 2017 |
|
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Common stock shares authorized (in Shares) | 120,000,000 | 60,000,000 | 120,000,000 | 120,000,000 | ||||||||
| Common stock par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Market sales agreement, description | In December 2020, pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock with an aggregate offering price of up to $50,000, with Jefferies acting as a sales agent. During the nine months ended September 30, 2022, the Company sold 229,044 shares of Common Stock under the ATM Agreement, at an average price of $1.19 per share, raising aggregate net proceeds of approximately $273, after deducting an aggregate commission of $8. | |||||||||||
| Contract liability (in Dollars) | $ 1,976 | |||||||||||
| Preferred stock, shares authorized (in Shares) | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Exercise price | $ 0.37 | $ 0.66 | $ 0.37 | $ 0.37 | ||||||||
| Vesting period | 4 years | |||||||||||
| Granted option shares (in Shares) | 20,000 | 290,000 | ||||||||||
| Vesting period | 1 year | |||||||||||
| Fair value at the grant date (in Dollars) | $ 127 | $ 1,428 | ||||||||||
| Shares of issued warrants (in Shares) | 2,974 | |||||||||||
| Warrant, description | The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. | |||||||||||
| Minimum [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Common stock shares authorized (in Shares) | 60,000,000 | |||||||||||
| Common stock par value | $ 0.0001 | |||||||||||
| Maximum [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Common stock shares authorized (in Shares) | 120,000,000 | |||||||||||
| Common stock par value | $ 0.0001 | |||||||||||
| Stock Options [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Employees consideration, description | On June 26, 2022, the Board of Directors approved the grant of 350,500 options to 53 employees, and one consultant under the Company’s 2019 Equity Incentive Plan, without consideration. | On March 29, 2022, the Board of Directors approved the grant of 1,153,500 options to 89 employees, three senior officers, one consultant, and five directors under the Company’s 2019 Equity Incentive Plan, without consideration. | ||||||||||
| Exercise price | $ 1.41 | |||||||||||
| Vesting period | 4 years | |||||||||||
| Maruho Agreement [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Common stock shares issued (in Shares) | 375,000 | |||||||||||
| Common stock per share | $ 8 | |||||||||||
| Total gross proceed (in Dollars) | $ 3,000 | |||||||||||
| Grant date fair value (in Dollars) | $ 1,024 | |||||||||||
| CFF Agreement [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Agreement type, description | the Company entered into a Securities Purchase Agreement with the Cystic Fibrosis Foundation (“CF Foundation”), an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (“CF”). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of all patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company would have the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion is less than $2.57, the Company shall have the right in its sole discretion to waive the second tranche payment and in such event the CF Foundation shall not have any right to receive additional shares. The Company concluded that the second tranche is a freestanding financial instrument. | |||||||||||
| Board of Directors [Member] | ||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||
| Exercise price | $ 0.66 | $ 0.66 | ||||||||||
| Vesting period | 4 years | |||||||||||